Biotricity Inc
NASDAQ:BTCY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biotricity Inc
Other
Biotricity Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotricity Inc
NASDAQ:BTCY
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
CardioComm Solutions Inc
XTSX:EKG
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Avricore Health Inc
XTSX:AVCR
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Diagnos Inc
XTSX:ADK
|
Other
-CA$248.1k
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-3%
|
|
|
N
|
NetraMark Holdings Inc
CNSX:AIAI
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biotricity Inc
Glance View
Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. The company is headquartered in Redwood City, California and currently employs 44 full-time employees. The company went IPO on 2015-10-26. The firm developed its Bioflux MCT technology, comprised of a monitoring device and an ECG reporting software component. The Bioflux device is comprised of a wet electrode and worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patient’s electrocardiogram (ECG) data for monitoring and diagnostic purposes. Both the device and software are in accordance with mobile cardiac telemetry (MCT) billing code standards, compliant with arrhythmia devices and alarms, and require 510000 clearance, which has been obtained. The Bioflux device has been developed, among other things, with global system for mobile communications (GSM) mobile chip for global cellular network compatibility; touch-screen liquid crystal display (LCD) viewer; and extended battery pack for an additional approximately 48 hours of battery life.
